Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Gabrovo – page 5

67 clinical trials in Gabrovo, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gabrovo at a glance
67
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

67 trials in Gabrovo

Open in trial search

Study on Fentanyl Nasal Spray and Morphine for Managing Postoperative Pain in Patients After Surgery

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Fentanyl Citrate
  • Sponsor:5med GmbH

Bladder cancer

Not recruiting

Study on UGN-102 (Mitomycin) for Treating Low Grade Non-Muscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Study of single-dose oritavancin safety and tolerability in children with acute bacterial skin and skin structure infections

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Aztreonam
  • Sponsor:Melinta Therapeutics LLC

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Poloxamer 407
  • Sponsor:Urogen Pharma Ltd.

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Cemiplimab to Platinum-Based Chemotherapy for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cilastatin
  • Sponsor:Spero Therapeutics Inc.

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Gabrovo

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, lung cancer, and bladder cancer. Research encompasses both targeted therapies and combination treatments.

  • Metastatic breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Prostate cancer interventions
  • Bladder cancer treatments

Special emphasis on developing targeted therapies for specific genetic mutations and combinations with immunotherapy.

02 Respiratory Medicine

Comprehensive research into respiratory conditions, with particular focus on chronic diseases and their management through innovative therapeutic approaches.

  • Asthma management studies
  • COPD treatment evaluations
  • Maintenance therapy optimization

Trials evaluate both single and combination therapies for improving lung function and quality of life.

03 Dermatology Studies

Advanced research in chronic skin conditions, investigating new therapeutic options for various dermatological disorders.

  • Plaque psoriasis treatments
  • Atopic dermatitis therapies
  • Long-term safety evaluations

Focus on developing both topical and systemic treatments for moderate to severe cases.

04 Cardiovascular Research

Innovative studies addressing heart conditions and related metabolic disorders, including new approaches to managing cholesterol and heart failure.

  • Heart failure treatments
  • Cholesterol management
  • Hypertriglyceridemia therapies

Emphasis on both preserved and reduced ejection fraction heart failure treatments.

05 Infectious Diseases

Research focusing on viral infections and preventive medicine, including vaccine development and infection management.

  • Influenza vaccine studies
  • Varicella vaccination
  • Urinary tract infection treatments

Special attention to vaccine safety and efficacy in various age groups.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.